Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil and Paclitaxel in Gynecologic Cancers
NCT00003334Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Mar 1997
- Primary completion
- Dec 2001
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegylated liposomal doxorubicin and paclitaxel in endometrial cancer (EC), fallopian tube cancer (PFTC) and sarcoma (2 arms), sponsored by NYU Langone Health. Primary endpoints: Response Rate and Duration of Response. Started Mar 1997; status: completed.
02
Drugs
pegylated liposomal doxorubicinpaclitaxel
03
Conditions
endometrial cancer (EC)fallopian tube cancer (PFTC)sarcoma
Beyond the preview
Go deeper on NCT00003334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003334.